• Welcome to WindMIL
    A platform for cell-based immuno-oncology therapy

About

WHAT WINDMIL Therapeutics DOES

When it comes to cell therapy – cell source matters. At WindMIL, we are harnessing the power of bone marrow derived lymphocytes (MILs) to develop ground-breaking immunotherapies to treat cancer patients. The bone marrow is a natural reservoir of T cells with unique advantages including inherent tumor-specificity. We have perfected an efficient and rapid process to extract, activate and expand MILs for future commercial applications. Our lead program is in a large Phase 2b study in high-risk multiple myeloma with additional programs in solid tumors using MILs advancing to the clinic. We are also advancing programs to supercharge MILs through genetic-modification.

Technology

WHAT MAKES MILS SPECIAL

MILsTM represent a novel class of cell therapy. Owing to their derivation from the bone marrow, a natural reservoir for memory T cells, MILs are marked by inherent tumor specificity, low toxicity, and long-term persistence. The ability to harness this long-term memory component is what differentiates MIL-therapy from other cell-therapy approaches, which rely predominantly on T cells found in the periphery.

MILs possess specificity for a broad array of tumor antigens. This reduces the likelihood of tumor escape via the loss of any single antigen. It also obviates the need to identify a particular tumor-specific antigen to target—the body has already done this—leaving only those T cells specific for nonself present in the population of MILs.
Bone marrow is a natural reservoir for memory T cells, and thus MILs are rich in this cell type. Memory T cells have been shown to be long-lasting and particularly effective at destroying tumors.
Human clinical experience has demonstrated that MILs are associated with only mild side effects, as well as a complete absence of the cytokine release syndrome seen with many other cell-based therapies. This profile enables the use of MILs earlier in treatment.
There is no need to genetically modify MILs to make them tumor-specific—they already possess specificity for tumor antigens. Avoiding genetic manipulation reduces the cost and complexity of the manufacturing process.

MEET OUR TEAM

THE EXPERTS THAT DRIVE WINDMIL

CONTACT

Reach out to Windmil

  • 1812 Ashland Avenue, 1st Floor, Suite 100, Baltimore, MD 21205
  • 410-558-1906